Device Trial Radar · NCT06075368
Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
757
Actual
Start
Mar 16, 2020
Primary completion
Dec 31, 2025
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Genoss Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy and safety of the GENOSS SES in patients with acute coronary syndrome (ACS) in real-world pratice.
Conditions
- Acute Coronary Syndrome
- Percutaneous Coronary Intervention
Interventions
GENOSS Sirolimus Eluting Coronary Stent SystemDevice
The GENOSS SES is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt chromium stent platform and thin strut.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device-oriented composite endpointTime frame: 12 months after the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.